Pancreatic Cancer Therapy
Research on pancreatic cancer therapy published by scientists at University of Regensburg, Department of Internal Medicine I
Published in Cancer Weekly, April 14th, 2009
Fresh data on pancreatic cancer are presented in the report 'Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.' According to a study from Regensburg, Germany, "Targeting the epidermal growth factor receptor pathway in pancreatic cancer seems to be an attractive therapeutic approach. This study assessed the efficacy of cetuximab plus the combination of gemcitabine/oxaliplatin in metastatic pancreatic cancer."
"Eligible subjects had histological or cytological diagnosis of metastatic pancreatic adenocarcinoma. The primary end point was response according to RECIST. Patients received cetuximab 400 mg...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-04-14)
More Articles from Cancer Weekly
- BG Medicine Inc.
BG Medicine Inc. Launches Galectin-3 Website and Commences Galectin-3 Assay Service for Clinical Research - Cancer
Palonosetron "Preferred" 5-HT3 Antagonist for Emesis Prevention in Oncology Patients Receiving Highly Emetogenic Chemotherapy - Cancer
Report Defines Need for Patients' Voice in Healthcare Reform - Cancer Gene Therapy
Data on cancer gene therapy detailed by researchers at University of Kuopio - Cancer Vaccines
Study results from M.A. Habel and colleagues in the area of cancer vaccines published - Celsion Corporation
Celsion Announces Promising ThermoDox® Clinical Results in Primary Liver Cancer Were Published in Expert Opinion - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
